Merck Serono and Intrexon in CAR-T deal

True to its word, Merck Serono is boosting its immune-oncology platform by signing an exclusive strategic collaboration and license agreement to develop and commercialize chimeric antigen receptor T-cell (CAR-T) cancer therapies with Intrexon for an upfront payment of $115m.